Literature DB >> 29794076

The future of kinase inhibitors for DLBCL?

Sarah E M Herman1.   

Abstract

Mesh:

Substances:

Year:  2018        PMID: 29794076      PMCID: PMC5969385          DOI: 10.1182/blood-2018-04-841908

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  8 in total

Review 1.  Emerging drugs for diffuse large B-cell lymphoma.

Authors:  Patrizia Mondello; Anas Younes
Journal:  Expert Rev Anticancer Ther       Date:  2015-02-05       Impact factor: 4.512

Review 2.  Tailoring front-line therapy in diffuse large B-cell lymphoma: who should we treat differently?

Authors:  Andrew Davies
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

Review 3.  The 2016 revision of the World Health Organization classification of lymphoid neoplasms.

Authors:  Steven H Swerdlow; Elias Campo; Stefano A Pileri; Nancy Lee Harris; Harald Stein; Reiner Siebert; Ranjana Advani; Michele Ghielmini; Gilles A Salles; Andrew D Zelenetz; Elaine S Jaffe
Journal:  Blood       Date:  2016-03-15       Impact factor: 22.113

4.  Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL.

Authors:  Paul M Barr; Gene B Saylors; Stephen E Spurgeon; Bruce D Cheson; Daniel R Greenwald; Susan M O'Brien; Andre K D Liem; Rosemary E Mclntyre; Adarsh Joshi; Esteban Abella-Dominicis; Michael J Hawkins; Anita Reddy; Julie Di Paolo; Hank Lee; Joyce He; Jing Hu; Lyndah K Dreiling; Jonathan W Friedberg
Journal:  Blood       Date:  2016-03-11       Impact factor: 22.113

5.  Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma.

Authors:  Wyndham H Wilson; Ryan M Young; Roland Schmitz; Yandan Yang; Stefania Pittaluga; George Wright; Chih-Jian Lih; P Mickey Williams; Arthur L Shaffer; John Gerecitano; Sven de Vos; Andre Goy; Vaishalee P Kenkre; Paul M Barr; Kristie A Blum; Andrei Shustov; Ranjana Advani; Nathan H Fowler; Julie M Vose; Rebecca L Elstrom; Thomas M Habermann; Jacqueline C Barrientos; Jesse McGreivy; Maria Fardis; Betty Y Chang; Fong Clow; Brian Munneke; Davina Moussa; Darrin M Beaupre; Louis M Staudt
Journal:  Nat Med       Date:  2015-07-20       Impact factor: 53.440

6.  Pan-SRC kinase inhibition blocks B-cell receptor oncogenic signaling in non-Hodgkin lymphoma.

Authors:  Elena Battistello; Natalya Katanayeva; Elie Dheilly; Daniele Tavernari; Maria C Donaldson; Luca Bonsignore; Margot Thome; Amanda L Christie; Mark A Murakami; Olivier Michielin; Giovanni Ciriello; Vincent Zoete; Elisa Oricchio
Journal:  Blood       Date:  2018-03-22       Impact factor: 22.113

7.  Tonic B-cell receptor signaling in diffuse large B-cell lymphoma.

Authors:  Ondrej Havranek; Jingda Xu; Stefan Köhrer; Zhiqiang Wang; Lisa Becker; Justin M Comer; Jared Henderson; Wencai Ma; John Man Chun Ma; Jason R Westin; Dipanjan Ghosh; Nicholas Shinners; Luhong Sun; Allen F Yi; Anusha R Karri; Jan A Burger; Tomasz Zal; R Eric Davis
Journal:  Blood       Date:  2017-06-23       Impact factor: 22.113

8.  Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells.

Authors:  R E Davis; K D Brown; U Siebenlist; L M Staudt
Journal:  J Exp Med       Date:  2001-12-17       Impact factor: 14.307

  8 in total
  1 in total

1.  Identification of an individualized RNA binding protein-based prognostic signature for diffuse large B-cell lymphoma.

Authors:  Yongzhi Xie; Ximei Luo; Haiqing He; Tao Pan; Yizi He
Journal:  Cancer Med       Date:  2021-03-21       Impact factor: 4.452

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.